Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › gilteritinib

gilteritinib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of gilteritinib

8 trials tracked of gilteritinib: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 1237 citations.

8Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 5
  1. Phase 3 A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation Completed · 1,237 cited
  2. Phase 3 A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) Completed · 182 cited
  3. Phase 3 A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy Completed · 126 cited
  4. Phase 2 Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  5. Phase 2 A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) Completed
  6. Phase 2 A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission Completed
Show 2 more trials
  1. Phase 2 A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. Completed
  2. Phase 2 Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network Meta-Analysis Compares FLT3 Inhibitors in Acute Myeloid Leukemia
Oncology Meta-analysis
Network Meta-Analysis Compares FLT3 Inhibitors in Acute Myeloid Leukemia Three FLT3 inhibitors show promise for AML patients
This network meta-analysis of 6128 acute myeloid leukemia patients compared FLT3 inhibitors. Gilteritinib and midostaurin improved complete …
Gilteritinib and midostaurin boost remission rates; gilteritinib and quizartinib improve survival in AML.
Frontiers May 11, 2026